An ongoing, randomized phase II study of Nivolumab plus Ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST)
Authors
Ahrens, M.Escudier, B.
Haanen, J.
Boleti, E.
Gross-Goupil, M.
Grimm, M. O.
Negrier, S.
Barthelemy, P.
Gravis, G.
Ivanyi, P.
Bedke, J.
Castellano, D.
Panic, A.
Mellado, B.
Maroto, P.
Rottey, S.
Zschabitz, S.
Florcken, A.
Bogemann, M.
Waddell, Thomas
Rodriguez, C. S.
Lorch, A.
Deckbar, D.
Hartmann, A.
Bergmann, L.
Affiliation
University Hospital Frankfurt, Medical Clinic II, Hematology and Oncology, Frankfurt, DeutschlandIssue Date
2022